Cryoport (CYRX) 10-Q2021 Q1 Quarterly report

Filed: 6 May 21, 5:11pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Bad

New words: addressing, aluminum, ancillary, area, ARP, Assembly, backlog, backup, billion, breadth, BREYANZI, British, build, CAA, capture, carryforward, Chinese, commensurate, companion, comparison, constrained, creation, crucial, CryosphereTM, CryoStork, CTSA, dedicated, demonstrated, demonstrating, destination, detailed, diligence, earnout, explanation, FD, FIFO, flight, footprint, forgoing, Freeze, geopolitical, GMP, gravitational, hardware, inbound, indefinite, Indian, indirect, inspection, IVF, jurisdiction, jurisdictional, kind, kit, kitting, knowledge, land, landscape, leadership, line, mobile, modification, Morgan, mover, nonstop, opportunity, ordinary, overarching, Parent, passively, payload, pending, portal, Portugal, proportionate, protein, Pty, reclassified, reconciliation, recreational, refinement, regularly, repaid, repayable, Rescue, restricted, royalty, RSU, run, Rupee, scale, settlement, shareholder, shelf, shop, short, sphere, Stanley, statuary, statutory, suite, Switzerland, Tactical, tissue, trace, UBS, UnITy, unmet, unregistered, usage, vertical, veterinary, Vitro, waive, waived, waiver, warehousing, Yuan

Removed: acceleration, accrual, added, adult, advertising, ambient, AmerisourceBergen, analyze, antigen, application, applied, Asia, Asian, authorizing, automated, BetaThalassemia, bio, blended, bluebird, booked, Brentwood, built, calculating, cancellation, CAR, certified, cGMP, children, chimeric, Ciloleucel, Codification, cold, collection, combination, compliant, contamination, continual, controlled, decision, decreased, desire, difficulty, directly, distancing, diverted, DLBCL, domestic, dry, Ecosystem, edge, eliminate, engineered, environment, EU, exclusively, execute, extension, family, fluctuation, follicular, foot, force, framework, Germany, Gilead, half, harmed, hinder, home, Hoofddorp, idecabtagene, ill, immunotherapy, implementation, important, infected, Integrating, intelligent, interested, interpret, Irvine, Kite, knowhow, launch, led, leverage, Livingston, location, low, lymphoma, maker, managed, mantle, maturation, meaningful, mechanical, mitigate, modify, nitrogen, November, offer, older, onsite, optimized, partner, people, percentage, personnel, physical, planning, PMBCL, posed, powered, precision, preliminary, priced, proactive, processing, profit, program, project, proprietary, prospectively, purpose, qualified, reactively, real, receptor, recording, recruiting, recyclable, reduced, refractory, refrigerated, regenerative, relapsed, relate, relocation, remove, representative, respond, retained, retrieval, retrospectively, reusable, rolling, room, sample, selection, shutdown, simplify, slowdown, SmartPakTM, social, spectrum, square, stage, staging, stoppage, submission, suspended, TDT, test, testing, traditional, trail, trusted, UK, unable, unparalleled, vapor, vast, verify, vicleucel, warrant, weighed, whichever, wholly, workflow, workforce, wrong, young

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated CYRX transcripts

CYRX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Cryoport, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jerrell W. Shelton, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


/s/ Jerrell W. Shelton

JERRELL W. SHELTON
President and Chief Executive Officer

May 6, 2021

In connection with the Quarterly Report of Cryoport, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robert S. Stefanovich, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


/s/ Robert S. Stefanovich

ROBERT S. STEFANOVICH
Chief Financial Officer

May 6, 2021

A signed original of this written statement required by Section 906 has been provided to Cryoport, Inc. and will be retained by Cryoport, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

This Certification is being furnished pursuant to Rule 15(d) and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act (15 U.S.C. 78r), or otherwise subject to the liability of that section. This Certification shall not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.